Ivermectin vs Remdesivir for Covid-19 treatment in the United States

A suspicious manipulation is observed in the treatments approved to cure or alleviate the symptoms of those infected with Covid-19.

Ivermectin is not authorized or approved by FDA for prevention or treatment of the virus. The National Institutes of Health’s (NIH) COVID-19 Treatment Guidelines Panel has also determined that there are currently insufficient data to recommend Ivermectin for treatment of COVID-19.

Therefore, the recommendation of the National Institue of Health for the Therapeutic Management of Hospitalized Adults With COVID-19 among patients who require oxygen is Remdesivir.

However, there is a serious discrepancy on the grounds on which this decision is based. In comparison, there are 21 Remdesivir studies showing a 22% improvement in patients. On the other hand, there are 27 Ivermectin studies showing 69% improvement in patients. Not only that, the mortality rate observed in these studies is much higher when the patient is treated with Remdesivir vs Ivermectin.

Is this a matter of vested interests? Is it a matter of profits favoring Gilead labs? The price of Remdesivir is $553 and may reach $1000 per treatment while the price of Ivermectin is $93.97 per treatment. While the first is an intravenous solution for injection, Ivermectin is an oral tablet. Furthermore, Ivermectin is much safer with mild side effects in some cases, while Remdesivir may have very serious side effects in some cases.

It is highly suspicious that the FDA and NIH chose to ignore that the World Health Organization (WHO) also ran randomized controlled trials on Remdesivir and found that it had no effect on COVID-19. In November, the WHO recommended against Remdesivir as a treatment.

To add insult to injury about these treatment decisions, National Institute of Allergy and Infectious Diseases Director Anthony S. Fauci, MD, insisted that data from a multinational randomized control trial showed that Gilead’s antiviral Remdesivir “has a clear-cut significant positive effect in diminishing time to recovery” for patients with COVID-19. “This will be the standard of care,” Fauci, a White House advisor on the pandemic, said during comments from the Oval Office. Fauci said the results, which have not yet been peer-reviewed, prove “that this drug can block this virus,”  and he added that “we think it’s opening the door to the fact that we now have the capability of treating” COVID-19.

Why would he insist on this treatment while prophylactic (preventive) treatment with Ivermectin has proven to offer better chances of controlling the pandemic?